Status:
RECRUITING
Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Dysbiosis
Eligibility:
All Genders
18+ years
Brief Summary
Lung cancer is the leading cancer in France in terms of mortality. The prognosis of the disease is closely correlated with the diagnostic stage and the majority of patients are diagnosed at a metastat...
Eligibility Criteria
Inclusion
- Adult (≥18 years)
- Confirmed diagnosis of NSCLC
- Stage IV or stage III-C NSCLC
- Immunotherapy treatment
Exclusion
- Refusal to reuse data for scientific research purposes
- Minor patient
- Disease stage below stage III-C
- Patient included in a clinical trial with an unknown randomization arm (double-blind study)
- Lack of relevant data on concomitant treatments, biology, or clinical outcomes
Key Trial Info
Start Date :
February 5 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 5 2026
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT07191171
Start Date
February 5 2025
End Date
February 5 2026
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Pneumologie - CHU de Strasbourg - France
Strasbourg, France, 67091